AlzeCure Pharma: Edison Open House Healthcare 2022

Published on 9 February 2022

AlzeCure Pharma is a clinical-stage biotech company based in Sweden focused on developing small molecule drugs for the treatment of Alzheimer’s disease (symptomatic and disease modifying) and pain (neuropathic and osteoarthritic).

• Tell us about the company and its key assets.
• Both Alzheimer’s disease and pain have been in the public spotlight recently. How has that affected your business?
• Please tell us about your pain assets.
• How large is the market for agents to deal with neuropathic pain?
• Please explain your TrkA-NAM project and its interest to large pharma.
• Do you see partnerships ahead?
• What is the current status of your two Alzheimer’s disease platforms and what are the next steps?
• What is the expected impact of the NeuroRestore asset on the patient?
• What is the expected impact of keeping Alzheimer’s patients out of full-time care for longer?
• Which milestones should investors look out for in the coming year?

Share this with friends and colleagues